Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025, primarily due to changes in market demand and competitive landscape affecting its antiviral and antifungal product lines [1] Financial Performance - The company achieved operating revenue of 537 million yuan, a year-on-year decrease of 18.28% [1] - The net profit attributable to shareholders was 17.17 million yuan, reflecting a year-on-year decline of 83.85% [1] - Basic earnings per share were reported at 0.04 yuan [1] Product Performance - Revenue and gross profit from antiviral products, particularly oseltamivir raw materials and formulations, significantly decreased due to changes in flu trends and competitive dynamics [1] - Revenue from antifungal raw materials also declined compared to the same period last year, attributed to fluctuations in customer demand and the high gross margin nature of these products [1] - Other raw material products saw revenue growth year-on-year; however, the transition of some products from the R&D phase to commercialization led to increased costs and price fluctuations, resulting in a decline in gross profit [1]